368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306). (23rd October 2018) - Bonnefoi, H; Levy, C; MacGrogan, G; Grellety, T; Asselain, B; Pulido, M; Everhard, S; Lemonnier, J; Gonçalves, A